A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs GLPG 2222 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Galapagos NV
- 17 Nov 2017 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Apr 2017 New trial record